The New England journal of medicine
The most recent articles from:
N. Engl. J. Med.
-
Randomized Controlled Trial Multicenter Study Comparative Study Clinical Trial
Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy.
Few studies have directly compared the renoprotective effects of angiotensin II-receptor blockers and angiotensin-converting-enzyme (ACE) inhibitors in persons with type 2 diabetes. ⋯ Telmisartan is not inferior to enalapril in providing long-term renoprotection in persons with type 2 diabetes. These findings do not necessarily apply to persons with more advanced nephropathy, but they support the clinical equivalence of angiotensin II-receptor blockers and ACE inhibitors in persons with conditions that place them at high risk for cardiovascular events.